7 Bay Area drugs that face competition from cheaper biotech 'generics'
Call them biosimilars, copycats, generics or follow-on biologics, but the age of cheaper versions of biotech drugs is on us.
Just last week, the Food and Drug Administration OK'd Zarxio — the first so-called biosimilar to win FDA approval— from Novartis AG (NYSE: NVS). Zarxio is a version of the Amgen Inc. (NASDAQ: AMGN) drug Neupogen, which increases infection-fighting white blood cell production in chemotherapy patients.
See our 'generics' slideshow. >>>>
At stake are tens of billions of…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Ron Leuty Source Type: news
More News: American Health | Biotechnology | Chemotherapy | Filgrastim | Food and Drug Administration (FDA) | Health | Health Management | Neupogen